ScinoPharm Taiwan Ltd (TW:1789) — Market Cap & Net Worth
Market Cap & Net Worth: ScinoPharm Taiwan Ltd (1789)
ScinoPharm Taiwan Ltd (TW:1789) has a market capitalization of $473.34 Million (NT$15.02 Billion) as of September 19, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #12647 globally and #472 in its home market, demonstrating a 2.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ScinoPharm Taiwan Ltd's stock price NT$19.00 by its total outstanding shares 790739000 (790.74 Million). Also see 1789 current and non-current assets for a full breakdown of the balance sheet.
ScinoPharm Taiwan Ltd Market Cap History: 2015 to 2026
ScinoPharm Taiwan Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.22 Billion to $473.34 Million (-5.28% CAGR). Also see 1789 operating cash flow for how efficiently the company converts equity into cash flow.
ScinoPharm Taiwan Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ScinoPharm Taiwan Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ScinoPharm Taiwan Ltd (1789) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.13x
ScinoPharm Taiwan Ltd's market cap is 0.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.05x
ScinoPharm Taiwan Ltd's market cap is 3.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $880.05 Million | $4.03 Billion | $658.69 Million | 0.22x | 1.34x |
| 2017 | $813.45 Million | $3.52 Billion | $422.37 Million | 0.23x | 1.93x |
| 2018 | $562.67 Million | $3.52 Billion | $442.98 Million | 0.16x | 1.27x |
| 2019 | $631.90 Million | $2.89 Billion | $216.66 Million | 0.22x | 2.92x |
| 2020 | $690.92 Million | $3.08 Billion | $282.07 Million | 0.22x | 2.45x |
| 2021 | $602.58 Million | $2.76 Billion | $243.47 Million | 0.22x | 2.47x |
| 2022 | $634.03 Million | $3.26 Billion | $353.22 Million | 0.19x | 1.80x |
| 2023 | $657.69 Million | $3.19 Billion | $287.06 Million | 0.21x | 2.29x |
| 2024 | $549.32 Million | $3.41 Billion | $339.35 Million | 0.16x | 1.62x |
| 2025 | $417.29 Million | $3.16 Billion | $136.95 Million | 0.13x | 3.05x |
Competitor Companies of 1789 by Market Capitalization
Companies near ScinoPharm Taiwan Ltd in the global market cap rankings as of September 19, 2026. Review 1789 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ScinoPharm Taiwan Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
ScinoPharm Taiwan Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, ScinoPharm Taiwan Ltd's market cap moved from $1.22 Billion to $ 473.34 Million, with a yearly change of -5.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$473.34 Million | +13.43% |
| 2025 | NT$417.29 Million | -24.04% |
| 2024 | NT$549.32 Million | -16.48% |
| 2023 | NT$657.69 Million | +3.73% |
| 2022 | NT$634.03 Million | +5.22% |
| 2021 | NT$602.58 Million | -12.79% |
| 2020 | NT$690.92 Million | +9.34% |
| 2019 | NT$631.90 Million | +12.30% |
| 2018 | NT$562.67 Million | -30.83% |
| 2017 | NT$813.45 Million | -7.57% |
| 2016 | NT$880.05 Million | -27.69% |
| 2015 | NT$1.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of ScinoPharm Taiwan Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $473.34 Million USD |
| MoneyControl | $473.34 Million USD |
| MarketWatch | $473.34 Million USD |
| marketcap.company | $473.34 Million USD |
| Reuters | $473.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract ma… Read more